Evaluate the Expression of uPA, PAI-1 in Human Gastric Cancer and its Correlation with the Angiogenesis by the Application of Tissue Microarray

References

1. ↵
   1. Quemener C,
   2. Gabison EE,
   3. Naïmi B, et al.

   Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007; 67: 9-15.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Duffy MJ,
   2. McGowan PM,
   3. Gallagher WM.

   Cancer invasion and metastasis: changing views. J Pathol 2008; 214: 283-293.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Offersen BV,
   2. Pfeiffer P,
   3. Andreasen P, et al.

   Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 2007; 56: 43-50.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Kaneko T,
   2. Koano H,
   3. Baba M, et al.

   Urokinase-type plaminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003; 94: 43-49.

   OpenUrlCrossRefPubMed
5. ↵
   1. Weinder N,
   2. Folkman J,
   3. Pozza F, et al.

   Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. Natl Cancer Inst 1992; 84: 1875-1887.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Kononen J,
   2. Bubendorf L,
   3. Kallioniemi A, et al.

   Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Duffy MJ.

   The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10: 39-49.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Wickstrom Sa, Veikkola T,
   2. Rehn M, et al.

   Endostatininduced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stressfibers in cultured human endothelial cells. Cancer Res 2001; 61: 6511-6610.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Chorostowska-Wynimko J,
   2. Swiercz R,
   3. Skrzypczak-Jankun E, et al.

   Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncol Rep 2004; 12: 1155-1162.

   OpenUrlPubMed
10. ↵
    1. Li YL,
    2. Ye ZR,
    3. Gong SL

    , Ed. Molecular Pathology. People’s Health Publisher. Beijing, 2002; 194-196 (Chinese).
11. ↵
    1. Steiner E,
    2. Pollow K,
    3. Hasenclever D.

    Role of urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Gynecol Oncol. 2008; 108: 569-576.

    OpenUrlCrossRefPubMed
12. ↵
    1. Werle B,
    2. Kotzsch M,
    3. Lah TT et al.

    Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004; 24: 4147-4161.

    OpenUrlAbstract/FREE Full Text
13. ↵
    1. Zhen Q,
    2. Tang ZY,
    3. Xue Q, et al.

    Invasion and metastasis of hepatocellular carcinoma in relation to urokinasetype plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000; 126: 641-646.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Fox SB,
    2. Taylor M,
    3. Grondahl-Hansen J, et al.

    Plasminogen activator inhibitor-1 as a measure of vascular remodeling in breast cancer. J pathol 2001; 195: 236-243.

    OpenUrlCrossRefPubMed
15. ↵
    1. Sakakibara T,
    2. Hibi K,
    3. Koike M, et al.

    Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005; 93: 799-803.

    OpenUrlCrossRefPubMedWeb of Science